Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients

In chronic myeloid leukemia (CML) and Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL) patients who fail imatinib treatment, BCR-ABL1 mutation profiling by Sanger sequencing (SS) is recommended before changing therapy since detection of specific mutations influences second-generation t...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Oncotarget
Main Authors: Soverini, Simona, De Benedittis, Caterina, Polakova, Katerina Machova, Linhartova, Jana, Castagnetti, Fausto, Gugliotta, Gabriele, Papayannidis, Cristina, Mancini, Manuela, Klamova, Hana, Salvucci, Marzia, Crugnola, Monica, Iurlo, Alessandra, Albano, Francesco, Russo, Domenico, Rosti, Gianantonio, Cavo, Michele, Baccarani, Michele, Martinelli, Giovanni
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2016
Teme:
Research Paper
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5008338/
https://ncbi.nlm.nih.gov/pubmed/26980736
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.8010
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki